Postural orthostatic tachycardia syndrome treatment guidelines

	Postural orthostatic tachycardia syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating POTS from Other Disorders
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiography
Other Diagnostic Studies
Treatment
ACC/AHA/ESC Treatment Guidelines
Medical Therapy
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Postural orthostatic tachycardia syndrome treatment guidelines On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Postural orthostatic tachycardia syndrome treatment guidelines All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Postural orthostatic tachycardia syndrome treatment guidelines
CDC on Postural orthostatic tachycardia syndrome treatment guidelines
Postural orthostatic tachycardia syndrome treatment guidelines in the news
Blogs on Postural orthostatic tachycardia syndrome treatment guidelines
Directions to Hospitals Treating Postural orthostatic tachycardia syndrome
Risk calculators and risk factors for Postural orthostatic tachycardia syndrome treatment guidelines

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

“

1) Increase salt and fluid intake (Level of Evidence: B)

2) Head-up tilt sleep (Level of Evidence: B)

3) Physical maneuvers (Level of Evidence: B)

4) Compression stockings (Level of Evidence: B)

1) Mineralocorticoids: Fludrocortisone (Level of Evidence: B)

2) Beta blockers: Bisoprolol (Level of Evidence: B)

3) Beta Blockers plus mineralocorticoids: Bisoprolol plus Fludrocortisone (Level of Evidence: B)

1) Central sympatholytic agents: Clonidine (Level of Evidence: B)

2) Peripherally acting: Midodrine (Level of Evidence: B)

3) Centrally acting: Methylphenidate (Level of Evidence: C)

4) Serotonin-specific reuptake inhibitor: Fluoxetine (Level of Evidence: C)

5) Others: Erythropoietin (Level of Evidence: B), Ergotamine/octroetide (Level of Evidence: B), Phenobarbitone (Level of Evidence: C)

1) Sinus node modification, catheter ablation (Level of Evidence: B)

”

↑ Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW, Stevenson WG, Tomaselli GF, Antman EM, Smith SC, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO, Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ (2003). "ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society". Journal of the American College of Cardiology. 42 (8): 1493–531. PMID 14563598. Retrieved 2012-09-12. Unknown parameter |month= ignored (help)